<DOC>
	<DOCNO>NCT02095587</DOCNO>
	<brief_summary>To evaluate pharmacokinetics , safety , tolerability IPI-145 administer subject chronic hepatic impairment match healthy subject .</brief_summary>
	<brief_title>Duvelisib Hepatically Impaired Subjects Compared Healthy Subjects</brief_title>
	<detailed_description>This nonrandomized , open-label , parallel-group , single oral dose study subject chronic hepatic impairment match ( age , sex , weight , BMI ) healthy subject . Subjects enrol 1 3 group base hepatic impairment grade : mild , moderate normal hepatic function . An optional severe hepatic impairment group enroll base data mild moderate hepatic impairment group comparison match healthy group . All subject receive single oral dose IPI-145 25 mg .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Men woman nonchildbearing potential 1870 year age Body Mass Index ( BMI ) : 18.0 38.0 kg/m2 . Healthy subject : good health , determine clinically significant finding clinical evaluation Hepatic impairment subject : confirm hepatic impairment &gt; 1 year etiology chronic alcoholism , chronic viral hepatitis ( B C ) , nonalcoholic steatohepatitis , autoimmune hepatitis , Wilson disease , alpha1 antitrypsin deficiency , glycogen storage disease , galactosemia Provided write informed consent prior study specific procedure Women childbearing potential Hepatic impairment subject : fluctuate rapidly deteriorate hepatic function , acute hepatitis , variceal bleeding within 8 week screen , history pancreatitis within 8 week screen , evidence hepatic encephalopathy &gt; Grade 1 , current unstable hematologic condition , and/or creatinine clearance &lt; 60 mL/min Healthy subject : positive screen test hepatitis B surface antigen , hepatitis C antibody ECG screen Day 1 show QTcF â‰¥ 450 msec healthy subject &gt; 500 msec hepatically impaired subject Evidence clinically significant medical condition History gastrointestinal disease surgery may affect drug absorption Positive indeterminate QuantiFERONTB Gold test screen Any active infection time screen admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>